| P50 | author | Shoji Kimura | Q89482497 |
| | Shahrokh Shariat | Q7462263 |
| | Beat Foerster | Q39051546 |
| | Mohammad Abufaraj | Q39051577 |
| | David D'Andrea | Q49486914 |
| | Andrea Mari | Q51049589 |
| P2860 | cites work | DNA Damage, Aging, and Cancer | Q22121931 |
| | Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family | Q24315643 |
| | The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain | Q24320162 |
| | Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 |
| | Translational implications of tumor heterogeneity | Q26822823 |
| | Bladder Tumor Heterogeneity: The Impact on Clinical Treatment | Q27686818 |
| | Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery | Q28074930 |
| | Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study | Q28139358 |
| | An antagonist decoy receptor and a death domain-containing receptor for TRAIL | Q28245153 |
| | The structural basis of XRCC1-mediated DNA repair | Q28259282 |
| | ERCC1-XPF endonuclease facilitates DNA double-strand break repair | Q28283273 |
| | A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation | Q28289092 |
| | Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance | Q28373910 |
| | Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells | Q28627137 |
| | Clonal evolution in cancer | Q29547696 |
| | Mechanisms of cancer drug resistance | Q29615849 |
| | The immune contexture in human tumours: impact on clinical outcome | Q29620667 |
| | Basement membranes: structure, assembly and role in tumour angiogenesis | Q29622882 |
| | Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. | Q30760649 |
| | Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base | Q33287299 |
| | Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes | Q33335165 |
| | MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. | Q33651005 |
| | HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic | Q33799406 |
| | The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation. | Q33832707 |
| | MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer | Q34138714 |
| | Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer | Q34226107 |
| | Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals | Q34393336 |
| | Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. | Q34603070 |
| | Targeting death and decoy receptors of the tumour-necrosis factor superfamily | Q34791120 |
| | Molecular aspects of resistance to antitumor platinum drugs. | Q34866688 |
| | Overview of bladder cancer trials in the Radiation Therapy Oncology Group | Q35098002 |
| | XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects | Q35173399 |
| | Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status | Q35187828 |
| | Molecular mechanisms of platinum resistance: still searching for the Achilles' heel | Q35943355 |
| | New insights on cell death from radiation exposure | Q36181711 |
| | DNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a Chinese population | Q36247880 |
| | Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy | Q36360770 |
| | Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy | Q36612270 |
| | Targeting the tumour microenvironment in ovarian cancer | Q36626921 |
| | Cancer initiation and progression: involvement of stem cells and the microenvironment | Q36765218 |
| | HMGB1 in cancer: good, bad, or both? | Q37067481 |
| | Platinum resistance: the role of DNA repair pathways | Q37100598 |
| | Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy | Q37241324 |
| | Cancer stem cells in solid tumors: an overview | Q37403282 |
| | Surveillance strategies after definitive therapy of invasive bladder cancer | Q37472555 |
| | Control of the adaptive immune response by tumor vasculature | Q37683575 |
| | P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake | Q37735490 |
| | Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue | Q38048249 |
| | ERCC5 is a novel biomarker of ovarian cancer prognosis | Q38289922 |
| | Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer | Q38335802 |
| | The Role of HMGB1 in Radioresistance of Bladder Cancer | Q38807569 |
| | Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer | Q38876830 |
| | Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells | Q39017796 |
| | Timing of DNA lesion recognition: Ubiquitin signaling in the NER pathway | Q39032808 |
| | Cancer Statistics, 2017. | Q39038674 |
| | Oncogenic FGFR3 gene fusions in bladder cancer | Q39240290 |
| | Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. | Q39617262 |
| | Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells | Q39690486 |
| | Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses | Q39829060 |
| | Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells | Q40065594 |
| | Attenuated expression of xeroderma pigmentosum group C is associated with critical events in human bladder cancer carcinogenesis and progression | Q40131356 |
| | Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells | Q40399026 |
| | Genomic evolution and chemoresistance in germ-cell tumours. | Q40447381 |
| | Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis | Q40578433 |
| | Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. | Q40668752 |
| | Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 |
| | Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma | Q40977600 |
| | Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma | Q41045256 |
| | Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems | Q41235735 |
| | Characterization of the azidopine and vinblastine binding site of P-glycoprotein | Q41598762 |
| | Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia | Q41714603 |
| | HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation | Q42700910 |
| | Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin | Q43513313 |
| | Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines | Q44039292 |
| | Genomic characterization of response to chemoradiation in urothelial bladder cancer | Q44338887 |
| | Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. | Q44693822 |
| | Polymorphisms in DNA repair and metabolic genes in bladder cancer | Q44701256 |
| | Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation | Q45823928 |
| | Predictors of cancer-specific mortality after disease recurrence following radical cystectomy | Q46489162 |
| | Death receptor 4 and bladder cancer risk | Q48022287 |
| | Intratumor heterogeneity: seeing the wood for the trees. | Q53097757 |
| | Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. | Q53340857 |
| | Roots and stems: stem cells in cancer. | Q53348663 |
| | Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand and death receptor genes contribute to susceptibility to bladder cancer. | Q53514312 |
| | Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. | Q53967094 |
| | TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. | Q54069963 |
| | DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. | Q54204908 |
| | Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk. | Q54314564 |
| | p53 and treatment of bladder cancer | Q59079146 |
| | Distinct methylation pattern and microsatellite instability in sporadic gastric cancer | Q73014737 |
| | Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population | Q80337032 |
| | Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients | Q82383679 |
| | Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer | Q83215025 |
| P433 | issue | 6 | |
| P304 | page(s) | 1081-1089 | |
| P577 | publication date | 2017-12-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | Genetic determinants for chemo- and radiotherapy resistance in bladder cancer | |
| P478 | volume | 6 | |